Literature DB >> 32182653

Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat.

David Dahlgren1, Maria-Jose Cano-Cebrián2, Tobias Olander1, Mikael Hedeland3,4, Markus Sjöblom5, Hans Lennernäs1.   

Abstract

Sufficient colonic absorption is necessary for all systemically acting drugs in dosage forms that release the drug in the large intestine. Preclinically, colonic absorption is often investigated using the rat single-pass intestinal perfusion model. This model can determine intestinal permeability based on luminal drug disappearance, as well as the effect of permeation enhancers on drug permeability. However, it is uncertain how accurate the rat single-pass intestinal perfusion model predicts regional intestinal permeability and absorption in human. There is also a shortage of systematic in vivo investigations of the direct effect of permeation enhancers in the small and large intestine. In this rat single-pass intestinal perfusion study, the jejunal and colonic permeability of two low permeability drugs (atenolol and enalaprilat) and two high-permeability ones (ketoprofen and metoprolol) was determined based on plasma appearance. These values were compared to already available corresponding human data from a study conducted in our lab. The colonic effect of four permeation enhancers-sodium dodecyl sulfate, chitosan, ethylenediaminetetraacetic acid (EDTA), and caprate-on drug permeability and transport of chromium EDTA (an established clinical marker for intestinal barrier integrity) was determined. There was no difference in jejunal and colonic permeability determined from plasma appearance data of any of the four model drugs. This questions the validity of the rat single-pass intestinal perfusion model for predicting human regional intestinal permeability. It was also shown that the effect of permeation enhancers on drug permeability in the colon was similar to previously reported data from the rat jejunum, whereas the transport of chromium EDTA was significantly higher (p < 0.05) in the colon than in jejunum. Therefore, the use of permeation enhancers for increasing colonic drug permeability has greater risks than potential medical rewards, as indicated by the higher permeation of chromium EDTA compared to the drugs.

Entities:  

Keywords:  absorption-modifying excipients; intestinal perfusion; oral peptide delivery; permeation enhancers; pharmaceutical development; regional intestinal permeability

Year:  2020        PMID: 32182653     DOI: 10.3390/pharmaceutics12030242

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  3 in total

1.  Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol.

Authors:  David Dahlgren; Maria-José Cano-Cebrián; Per M Hellström; Alkwin Wanders; Markus Sjöblom; Hans Lennernäs
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

2.  Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats.

Authors:  Maria-José Cano-Cebrián; David Dahlgren; Fredrik Kullenberg; Karsten Peters; Tobias Olander; Markus Sjöblom; Hans Lennernäs
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

3.  Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats.

Authors:  David Dahlgren; Tobias Olander; Markus Sjöblom; Mikael Hedeland; Hans Lennernäs
Journal:  Acta Pharm Sin B       Date:  2021-01-05       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.